Publication
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Authors not recorded
Nat Genet2019PMID 30643254PMC6365097stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (2)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 2
- drugImmune Checkpoint Inhibitorcivic_curation1.00
- variantHighcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 30643254
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| High1 | ||||||||
| Immune Checkpoint Inhibitor | Solid Tumors, AdvancedUNRESOLVED | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID12578This retrospective study examined the association between TMB and clinical response to immune checkpoint inhibitor (ICI) across multiple cancer types. 1,662 advanced cancer patients treated with at … (full text at CIViC) PMID 30643254 · Samstein et al., 2019 · Open in CIViC | civic |